Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10708MR)

This product GTTS-WQ10708MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ALB&IL17A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized; Vicugna pacos (alpaca)
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3605
UniProt ID P02768; Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10708MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2865MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ15105MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ14695MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ15821MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ15579MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ4253MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ6915MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ15027MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SNDX-6352
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW